Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL712301 | 0.80 | EPHX1 (0.32) | EPHX1 | |
| SCHEMBL7262219 | 0.78 | MEN1 (0.31) | — | |
| SCHEMBL5074508 | 0.77 | UGT2B7 (0.33) | EPHX1 | |
| SCHEMBL12132583 | 0.76 | — | — | |
| SCHEMBL25763373 | 0.75 | — | — | |
| SCHEMBL9099612 | 0.75 | — | — | |
| SCHEMBL8909519 | 0.74 | — | — | |
| SCHEMBL10976402 | 0.74 | ALDH1A1 (0.33) | — | |
| SCHEMBL713643 | 0.74 | — | — | |
| SCHEMBL4189522 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617777-B2 | GPR84 antagonists and uses thereof | Liminal Biosciences Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| EP-4288427-A1 | GPR84 ANTAGONISTS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2023-12-13 | — | — | EP | disclosed |
| CN-117098757-A | GPR84 antagonists and uses thereof | 里米诺生物科学有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230113202-A1 | GPR84 ANTAGONISTS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2023-04-13 | — | — | US | disclosed |
| WO-2022167457-A1 | GPR84 ANTAGONISTS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2022-08-11 | — | — | WO | disclosed |
| US-8124780-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8124780-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8124780-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8124780-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| CN-101160306-B | Benzimidazole compounds | EISAI R&D MAN CO LTD | 2011-11-02 | — | — | CN | disclosed |
| WO-2007122686-A1 | BENZIMIDAZOLE COMPOUNDS | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2007-11-01 | — | — | WO | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| WO-2006112442-A1 | BENZIMIDAZOLE COMPOUND | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113202-A1 | GPR84 ANTAGONISTS AND USES THEREOF | GPR84, GPR88, GPR65 | EPHX1 800/4885NPC1 315/4885RAB9A 2822/4885 |
| US-12617777-B2 | GPR84 antagonists and uses thereof | GPR84, GPR88, GPR3 | EPHX1 2069/4885NPC1 433/4885RAB9A 3253/4885 |
| US-20070010542-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | EPHX1 1073/4885NPC1 1355/4885RAB9A 1686/4885 |
| US-20070015782-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | EPHX1 1073/4885NPC1 1355/4885RAB9A 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.